Condition: Hereditary Angioedema (HAE) · Sponsor: Ionis Pharmaceuticals, Inc.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).
This description comes directly from the study's public registry record.
Ionis Pharmaceuticals, Inc. · (844) 201-3192 · IonisDonidalorsenPediatric@clinicaltrialmedia.com
Always discuss trial participation with your own doctor first.
| Ionis Investigative Site | Santa Monica, California, United States | Recruiting |
| Ionis Investigative Site | Miami, Florida, United States | Recruiting |
| Ionis Investigative Site | St Louis, Missouri, United States | Recruiting |
| Ionis Investigative Site | Cincinnati, Ohio, United States | Recruiting |
| Ionis Investigative Site | Hershey, Pennsylvania, United States | Recruiting |
| Ionis Investigative Site | Milan, Italy | Recruiting |
| Ionis Investigative Site | Padova, Italy | Recruiting |
| Ionis Investigative Site | San Donato Milanese, Italy | Recruiting |
| Ionis Investigative Site | Warsaw, Poland | Recruiting |
| Ionis Investigative Site | Barcelona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07298447